Rheumatology
Latest news
98 articles · 20 / page
Revolutionizing Ankylosing Spondylitis Assessment: AI-Driven Severity Inspection Model Enhances Diagnostic Precision
An AI-based model for assessing ankylosing spondylitis severity using spinal X-rays and mSASSS demonstrates high accuracy, offering clinicians a rapid, reliable tool and reducing human resource demands.
Type II Cryoglobulinemic Vasculitis: A Marker of Severe Prognosis in Primary Sjögren Disease
A French multicenter study identifies type II cryoglobulinemic vasculitis in primary Sjögren disease as a strong predictor of lymphoma and mortality, necessitating enhanced clinical vigilance.
Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.
Fine Particulate Matter Exposure Significantly Increases SLE Risk
A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient managemen
Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
Functional MRI Brain Activation as a Predictor of Response to TNF Inhibition in Rheumatoid Arthritis: Insights from the PreCePra Phase 3 Study
A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.
Sarilumab in Relapsing Polymyalgia Rheumatica: Clinical Efficacy and Patient-Reported Outcomes from Recent Phase 3 Trials
Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.
Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence
Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unrespon
FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease
The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.
Polymyalgia Rheumatica Not Associated with Increased Mortality: Insights from a 38-Year Norwegian Cohort Study
A 38-year prospective study in Southern Norway demonstrates that isolated polymyalgia rheumatica (PMR) does not increase all-cause mortality compared to matched population controls, with men showing even lower mortality risk.
Rituximab Shows No Superiority Over Conventional Therapy for EGPA Remission Induction
A phase 3 randomized trial found rituximab no more effective than standard glucocorticoid-based therapy in inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), with comparable safety and relapse profiles.
Low Lupus Activity as a Predictive Target in Lupus Nephritis: A Clinical Appraisal of LLDAS
Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.
Johns Hopkins Hospital Leads U.S. News Rheumatology Rankings
Highlight Rheumatologic diseases—including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathies, vasculitides, and connective tissue disorders—represent a...
Personal and Household Pesticide Exposure Linked to Increased Risk of Rheumatoid Arthritis in Female Farm Spouses
New evidence links direct and indirect exposure to specific agricultural pesticides with increased risk of incident rheumatoid arthritis among female spouses of licensed pesticide applicators.
WHO Releases Comprehensive Guidelines for Managing Sickle Cell Disease in Pregnancy
New WHO guidelines offer evidence-based approaches to improve care for pregnant women with sickle cell disease, focusing on treatment and maternal outcomes.
Browse by specialty
Open language-specific specialty feeds and department pages.